Next Article in Journal
The Spectrum of Esophagitis in Patients Living with HIV—A Scoping Review
Previous Article in Journal
Continuous Versus Intermittent Infusion of Beta-Lactam Antibiotics: Where Do We Stand Today? A Narrative Review
 
 
GERMS is published by MDPI from Volume 15 Issue 4 (2025). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with the former publisher Infection Science Forum.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Emerging Role of Pseudomonas aeruginosa in Diarrhea: Where We Stand

by
Mansoor Khaledi
1,
Ahdiyeh Saghabashi
2 and
Hossein Ghahramanpour
3,*
1
Department of Microbiology and Immunology, School of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran
2
Department of Microbiology, Faculty of Sciences, Agriculture and Modern Technology, Shiraz Branch, Islamic Azad University, Shiraz, Iran
3
Department of Bacteriology, Faculty of medical sciences, Tarbiat Modares University, Tehran, Iran
*
Author to whom correspondence should be addressed.
GERMS 2024, 14(2), 179-188; https://doi.org/10.18683/germs.2024.1429
Submission received: 22 February 2024 / Revised: 11 June 2024 / Accepted: 12 June 2024 / Published: 30 June 2024

Abstract

Although Pseudomonas aeruginosa (PA) hasn’t been considered as a recognized agent of diarrhea, this organism is able to cause community-acquired diarrhea accompanied by fever and sepsis, as well as antibiotic-associated diarrhea (AAD). Antibiotic resistance rates in stool isolates of PA are generally lower compared to other infection sites, but in patients with AAD, there are reports of resistance to most of the antibiotic classes in these isolates. PA, along with other opportunistic pathogens like Clostridioides difficile, can cause AAD. Therefore, it is suggested to examine stool samples of patients with predisposing factors such as intensive care unit (ICU) admission and long-time antibiotic treatment, especially with cephalosporins, for both C. difficile and PA.

Introduction

Diarrhea, a common gastrointestinal disorder is classically defined as the discharge of loose or watery stools, typically at least three times a day. People with diarrhea may exhibit symptoms such as nausea, abdominal pain, fecal incontinence and an urgent need to use the bathroom [1,2].
In between, bacterial diarrhea is responsible for a big part of diarrhea cases, which accounts for about 30% of all diarrheas [3,4]. Notably, several bacterial organisms like E. coli, Shigella, Salmonella, and Campylobacter are recognized as the main agents responsible for bacterial diarrhea [5,6,7].
Although some uncommon organisms are reported to cause diarrhea, not in recent years, but since the onset of the 20th century, Pseudomonas aeruginosa (PA) has been reported as the causative agent of diarrhea, mainly in case reports [8,9].
Although this organism is known as a common cause of nosocomial infections, presenting as pneumonia, surgical site infections, sepsis and urinary tract infections, for the first time, in 1918 and in Shanghai, China, occurrences of what was then named “Shanghai fever” were reported. These incidents of community-acquired diarrhea were accompanied with fever, sepsis and growth of PA from blood or other sterile body sites [10,11].
According to the classification proposed by Chuang et al., PA is causative agent of four distinct groups of gastrointestinal infections: Shanghai fever, enterocolitis, infectious diarrhea, and antibiotic-associated diarrhea [12].
Although there have been a number of case reports in this regard, the necessity of a review to connect current data about PA diarrhea is apparent. In this review, we aim to inspect our knowledge about the role of PA in the occurrence of diarrhea, clinical manifestations of patients, the underlying risk factors, and antibiotic resistance patterns of PA isolates and finally, prevention of PA diarrhea.

Colonization by PA in human gut

PA is an opportunistic pathogen and it is not usually considered as a normal member of the flora in the human body, and therefore the gut microbiota. Nonetheless, it is worth noting that this organism is an unusual colonizer of the human gut, affecting less than 10% of healthy individuals [13,14,15].
The remarkable aspect is how PA accomplishes this colonization. Previous studies suggest that PA exploits specific lectins such as PA-IL, and PA-IIL for binding to surface antigens on intestinal epithelium cells and facilitates its initial colonization [16,17]. Subsequently, the bacterium uses ExoS to bind to the FXYD3 factor and disrupt intracellular tight junctions, making PA able to penetrate through the intestinal epithelial barrier [18]. These isolates could potentially translocate to other body sites and cause bacteremia, pneumonia, urinary tract infection and skin involvement, so that the gut effectively serves as the reservoir for PA [19].
Past studies have shown that PA colonization is associated with various risk factors. One significant factor is gut microbiota dysbiosis, mainly due to exposure to antibiotics during hospitalization. This dysbiosis reduces the microbial population diversity and creates the opportunity for the growth of multidrug-resistant or MDR isolates, non-susceptible to at least one agent in at least 3 antibiotic classes, and extensively drug-resistant PA isolates or XDR, non-susceptible to at least one agent in all but 1 or 2 antibiotic classes [19,20,21,22].
For instance, piperacillin-tazobactam prescription is associated with a decreased population of commensal lactobacillus and Clostridiales taxa with a concomitant increase in carbapenem-resistant PA colonization acquisition among patients in the intensive care unit (ICU) [23].
Additionally, comparing to healthy people, cancer patients, individuals hospitalized in the ICU and those with hematological malignancies demonstrate a higher colonization rate, contributing to the development of PA infections [24,25].
Among ICU patients, a significant proportion are colonized with PA on admission, so that the gastrointestinal tract colonization rate among these individuals can reach up to 27%. Also, it has been shown that there is a higher risk of PA-related clinical infection in non-colonized patients, which can result in future infection with the same strain [26,27]. Since this colonization has significant consequences for the risk of infection in vulnerable patient populations, it is crucial to understand the factors that contribute to colonization.

The origin and clinical manifestations of PA diarrhea

According to the reviewed literature, PA diarrhea could be divided into two main groups: 1. hospital-acquired diarrhea (HAD) and 2. community-acquired diarrhea (CAD). HAD is defined as the occurrence of diarrhea after ≥3 days hospitalization, that was not present at the time of admission, while CAD is diarrhea with onset less than 3 days after admission [28,29,30].
Furthermore, the difference between PA carriage and PA causing diarrhea should be further clarified. In particular, some cases may yield pure or predominant growth of PA in their stool while diarrhea or other complications are not observed and the person is healthy [13,19,31,32].
As mentioned in Table 1, a considerable number of cases are related to antibiotic associated diarrhea (AAD) that mainly occurs in HAD adult patients.
A long period of hospitalization and exposure to a variety of antibiotics may results in this phenomenon. We know under antibiotic pressure selection, population of opportunistic pathogens like Clostridioides difficile overcome the normal gut flora and proceed to gastroenteritis and diarrhea [33]. Similarly, evidences show other organism as well PA cause AAD, hence, it is proposed stool samples of these patients to be investigated for C. difficile and PA [34,35,36,37,38].
In a similar manner to AAD of adults, there are some reports of AAD in young children and infants. In this age group, AAD could be relevant to PA diarrhea incidence. For example, in the study by CH Chuang et al. about 56% of children with PA positive stool culture were dedicated to AAD cases that did not have underlying diseases [12]. Risk factors for AAD in children include the administration of cephalosporins and admission to ICU [39].
Another important aspect to consider is nonPA diarrhea despite of PA detection in stool culture, meaning the bacterium has colonized the host intestine, but another agent causes diarrhea. A variety of viruses, protozoa, or non-infectious situation agents like reactions to medicines and underlying diseases result in diarrhea [40,41].
Some researchers have explored other suspicious organisms in diarrhea cases. Concomitant detection of PA with Salmonella and Aeromonas species [42], rotavirus[12] and C. difficile[35] or a drug induced diarrhea in immunocompromised patients like leukemia patients [43]. Chemotherapy drugs are well known to cause diarrhea, which is a common side effect. Also, like antibiotics, they are considered to perturb gut normal flora and induce diarrhea, of course, there is little data about the role of PA in this case [43,44,45,46].
Conversely, CAD reports have predominantly been reported in infants and young children. Most of described cases had developed sepsis and ecthyma gangrenosum as the result of systemic infection with PA. In some patients, necrotizing enteritis and bowel perforation with the need for prompt surgical intervention were observed [47,48,49].
A considerable common point of these cases is that the patients have been previously healthy without underlying disease [8,42,43,47,49,50,51,52]. Considering all these, a probable explanation may go back to the deficient nature and low diversity of infants’ gut microbiota compared with adults, so that infants before age 1 are susceptible to develop diarrhea by different pathogens. About PA it is postulated that in the neonatal intestine, colonization and overgrowth of this organism will be followed by intestinal involvement and sepsis [49,52,53,54,55].
Regardless of which HAD or CAD groups the cases belong to, the mechanism by which PA causes diarrhea remains rather unclear. Unlike well-known bacteria that are specifically considered enteric pathogens and possess determined virulence factors to cause gastroenteritis in humans, this doesn’t apply to PA.
Previous studies have focused on various virulence factors of PA. Fakhkhari et al. compared intestinal PA isolates with environmental isolates and found that toxinrelated genes lasB, aprA, exoY, and exoS were significantly more frequent in diarrhea isolates [56].
Chuang et al. observed the isolates from Shanghai fever had a higher frequency of exoU and more rapidly penetrated through MDCK cell monolayers than respiratory and laboratory strains, probably explaining the mechanism by which PA crosses through intestinal cells and reaches the bloodstream [48].
In the study by Chowdhury et al., the wholegenome sequencing analysis of suspicious PA causing diarrhea revealed this isolate contained more than ten genes linked to toxin-associated factors (doc, phd, ratA, vapC, relE) and several key virulence factors such as mviM, bvgS, hudA, and pqsR, as well as the presence of the type 3 secretion system (T3SS) and the ability of in vivo fluid accumulation may be related to diarrheal infection [57].
An older study by Adlard et al. found that a considerable number of isolates indicated the ability to adhere to HEp-2 cells and showed twitching motility by type IV pili presumed to help PA gut colonization [58].
Considering the non-overlapping results of these studies, the limited number of conducted studies, and the high diversity of PA virulence factors, it could be concluded that there is still a gap in our knowledge of PA pathogenesis associated with diarrhea.

Antibiotic resistance in PA causing diarrhea

Another important aspect of these isolates not to be neglected is their resistance to antibiotic classes. According to Table 1 and other related studies, PA isolates from CAD cases were sensitive to most antibiotics, while HAD isolates showed a higher resistance rate, which is more noticeable in cases where patients received longterm antibiotic treatment and we defined them as AAD. Therefore, a variety of antibiotics were prescribed to cure the diarrhea, with ciprofloxacin being the most common choice. Interestingly, Chowdhury et al. reported an XDR PA isolate resistant to all antibiotics except for colistin. Despite such high resistance, however, the patient got intravenous ceftriaxone and doxycycline and recovered after 10 days. The authors noted that ceftriaxone possibly decreased the excretion levels of doxycycline from the body resulting in an elevation of its concentration in the serum [57].
In the study by Fakhkhari et al., 25.5% of stool isolates showed an MDR phenotype; all of them were sensitive to meropenem and had low resistance rates to ciprofloxacin, aztreonam and gentamicin [56].
Hu et al., in a group of hospitalized patients but without gastroenteritis, reported 41.3% resistance to carbapenems like meropenem [20]. Although we don’t have more data to give a comparison between these results and those from PA isolated from other infection sites, it could be concluded that the antibiotic resistance rate in stool isolates is generally lower [59,60,61].

The prevention of Pseudomonas aeruginosaassociated diarrhea and conclusion

Depending on the type of PA diarrhea, if it belongs to AAD diarrhea, the adjustment of prescribed antibiotics according to the isolate drug sensitivity pattern and cessation of antibiotic therapy with extended spectrum choices would be helpful [35,36,37]. In addition, high-risk patients like infants, immunocompromised and high-risk people need to be screened for the presence of PA in their stool samples. Despite the few reports of PA-associated diarrhea, it is not impossible to observe PA in the stool cultures of patients with diarrhea, especially those with special conditions reviewed in Table 1 and other studies [49,50,56]. Therefore, we recommend physicians and laboratory technicians should be more alert to the possibility of diarrhea by PA beside common fecal pathogens and perform antimicrobial susceptibility testing for suspicious non-fermenter colonies on XLD, MacConkey’s agar or other bacterial culture media [62].

Author Contributions

HG, MK: design of study. HG, MK: acquisition of data. HG, MK, AS: evaluation of data, preparation of the manuscript. HG, MK, AS: assessment of data. All authors read and approved the final manuscript.

Funding

None to declare.

Institutional Review Board Statement

This article does not contain any studies with human participants or animals performed by any of the authors.

Data Availability Statement

Available from the corresponding author upon reasonable request.

Conflicts of Interest

All authors—none to declare.

References

  1. Riddle, M.S.; DuPont, H.L.; Connor, B.A. ACG clinical guideline: Diagnosis, treatment, and prevention of acute diarrheal infections in adults. Am. J. Gastroenterol. 2016, 111, 602–622. [Google Scholar] [CrossRef]
  2. Keusch, G.T.; et al. Chapter 19. Diarrheal diseases. In Disease control priorities in developing countries, 2nd ed.; Oxford University Press: Oxford, UK, 2006; p. 37188. [Google Scholar] [CrossRef]
  3. Talan, D.; Moran, G.J.; Newdow, M.; et al. Etiology of bloody diarrhea among patients presenting to United States emergency departments: Prevalence of Escherichia coli O157:H7 and other enteropathogens. Clin. Infect. Dis. 2001, 32, 573–580. [Google Scholar] [CrossRef]
  4. Tam, C.C.; O’Brien, S.J.; Tompkins, D.S.; et al. Changes in causes of acute gastroenteritis in the United Kingdom over 15 years: Microbiologic findings from 2 prospective, population-based studies of infectious intestinal disease. Clin. Infect. Dis. 2012, 54, 1275–1286. [Google Scholar] [CrossRef]
  5. Metreveli, M.; Bulia, S.; Shalamberidze, I.; et al. Campylobacteriosis, shigellosis and salmonellosis in hospitalized children with acute inflammatory diarrhea in Georgia. Pathogens 2022, 11, 232. [Google Scholar] [CrossRef] [PubMed]
  6. Shen, H.; Zhang, J.; Li, Y.; et al. The 12 gastrointestinal pathogens spectrum of acute infectious diarrhea in a sentinel hospital, Shenzhen, China. Front. Microbiol. 2016, 7, 1926. [Google Scholar] [CrossRef] [PubMed]
  7. Jafari, F.; Shokrzadeh, L.; Hamidian, M.; SalmanzadehAhrabi, S.; Zali, M.R. Acute diarrhea due to enteropathogenic bacteria in patients at hospitals in Tehran. Jpn. J. Infect. Dis. 2008, 61, 269–273. [Google Scholar] [CrossRef] [PubMed]
  8. Viola, L.; Langer, A.; Pulitanò, S.; Chiaretti, A.; Piastra, M.; Polidori, G. Serious Pseudomonas aeruginosa infection in healthy children: Case report and review of the literature. Pediatr. Int. 2006, 48, 330–333. [Google Scholar] [CrossRef] [PubMed]
  9. Marcon, A.P.; Gamba, M.A.; Vianna, L.A. Nosocomial diarrhea in the intensive care unit. Braz. J. Infect. Dis. 2006, 10, 384–389. [Google Scholar] [CrossRef]
  10. Dold, H. On pyocyaneus sepsis and intestinal infections in Shanghai due to Bacillus pyocyaneus. Chin. Med. J. 1918, 32, 435. [Google Scholar]
  11. Reynolds, D.; Kollef, M. The epidemiology and pathogenesis and treatment of Pseudomonas aeruginosa infections: An update. Drugs 2021, 81, 2117–2131. [Google Scholar] [CrossRef]
  12. Chuang, C.H.; Janapatla, R.P.; Wang, Y.H.; et al. Pseudomonas aeruginosa-associated diarrheal diseases in children. Pediatr. Infect. Dis. J. 2017, 36, 1119–1123. [Google Scholar] [CrossRef]
  13. Estepa, V.; Rojo-Bezares, B.; Torres, C.; Sáenz, Y. Faecal carriage of Pseudomonas aeruginosa in healthy humans: Antimicrobial susceptibility and global genetic lineages. FEMS Microbiol. Ecol. 2014, 89, 15–19. [Google Scholar] [CrossRef]
  14. Valenza, G.; Tuschak, C.; Nickel, S.; Krupa, E.; LehnerReindl, V.; Höller, C. Prevalence, antimicrobial susceptibility, and genetic diversity of Pseudomonas aeruginosa as intestinal colonizer in the community. Infect. Dis. 2015, 47, 654–657. [Google Scholar] [CrossRef] [PubMed]
  15. Ruiz-Roldán, L.; Bellés, A.; Bueno, J.; et al. Pseudomonas aeruginosa isolates from Spanish children: Occurrence in faecal samples, antimicrobial resistance, virulence, and molecular typing. Biomed. Res. Int. 2018, 2018, 8060178. [Google Scholar] [CrossRef] [PubMed]
  16. Gilboa-Garber, N. Psuedomonas aeruginosa lectins. Methods Enzymol. 1982, 83, 378–385. [Google Scholar] [CrossRef] [PubMed]
  17. Laughlin, R.S.; Musch, M.W.; Hollbrook, C.J.; Rocha, F.M.; Chang, E.B.; Alverdy, J.C. The key role of Pseudomonas aeruginosa PA-I lectin on experimental gut-derived sepsis. Ann. Surg. 2000, 232, 133–142. [Google Scholar] [CrossRef] [PubMed]
  18. Okuda, J.; Hayashi, N.; Okamoto, M.; et al. Translocation of Pseudomonas aeruginosa from the intestinal tract is mediated by the binding of ExoS to an Na,K-ATPase regulator, FXYD3. Infect Immun. 2010, 78, 4511–4522. [Google Scholar] [CrossRef] [PubMed]
  19. Ohara, T.; Itoh, K. Significance of Pseudomonas aeruginosa colonization of the gastrointestinal tract. Intern. Med. 2003, 42, 1072–1076. [Google Scholar] [CrossRef]
  20. Hu, Y.; Qing, Y.; Chen, J.; et al. Prevalence, risk factors, and molecular epidemiology of intestinal carbapenemresistant Pseudomonas aeruginosa. Microbiol Spectr. 2021, 9, e0134421. [Google Scholar] [CrossRef]
  21. Wang, L.; He, Y.; Li, H.; Ai, Q.; Yu, J. The microbiota protects against Pseudomonas aeruginosa pneumonia via γδ T cell-neutrophil axis in mice. Microbes Infect. 2020, 22, 294–302. [Google Scholar] [CrossRef]
  22. Horcajada, J.P.; Montero, M.; Oliver, A.; et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev. 2019, 32, e00031-19. [Google Scholar] [CrossRef]
  23. Pettigrew, M.M.; Gent, J.F.; Kong, Y.; et al. Gastrointestinal microbiota disruption and risk of colonization with carbapenem-resistant Pseudomonas aeruginosa in intensive care unit patients. Clin. Infect. Dis. 2019, 69, 604–613. [Google Scholar] [CrossRef] [PubMed]
  24. Markou, P.; Apidianakis, Y. Pathogenesis of intestinal Pseudomonas aeruginosa infection in patients with cancer. Front. Cell Infect. Microbiol. 2014, 3, 115. [Google Scholar] [CrossRef] [PubMed]
  25. Wheatley, R.M.; Caballero, J.D.; van der Schalk, T.E.; et al. Gut to lung translocation and antibiotic mediated selection shape the dynamics of Pseudomonas aeruginosa in an ICU patient. Nat. Commun. 2022, 13, 6523. [Google Scholar] [CrossRef]
  26. Cohen, R.; Babushkin, F.; Cohen, S.; et al. A prospective survey of Pseudomonas aeruginosa colonization and infection in the intensive care unit. Antimicrob. Resist. Infect. Control. 2017, 6, 7. [Google Scholar] [CrossRef]
  27. Gómez-Zorrilla, S.; Camoez, M.; Tubau, F.; et al. Antibiotic pressure is a major risk factor for rectal colonization by multidrug-resistant Pseudomonas aeruginosa in critically ill patients. Antimicrob. Agents Chemother. 2014, 58, 586370. [Google Scholar] [CrossRef]
  28. Polage, C.R.; Solnick, J.V.; Cohen, S.H. Nosocomial diarrhea: Evaluation and treatment of causes other than Clostridium difficile. Clin. Infect. Dis. 2012, 55, 982–989. [Google Scholar] [CrossRef] [PubMed]
  29. Ford-Jones, E.L.; Mindorff, C.M.; Gold, R.; Petric, M. The incidence of viral-associated diarrhea after admission to a pediatric hospital. Am. J. Epidemiol. 1990, 131, 711–718. [Google Scholar] [CrossRef]
  30. McFarland, L.V. Diarrhea acquired in the hospital. Gastroenterol. Clin. North. Am. 1993, 22, 563–577. [Google Scholar] [CrossRef]
  31. Chuang, C.H.; Janapatla, R.P.; Wang, Y.H.; Chang, H.J.; Chen, C.L.; Chiu, C.H. Association between histo-blood group antigens and Pseudomonas aeruginosa-associated diarrheal diseases. J. Microbiol. Immunol. Infect. 2023, 56, 367–372. [Google Scholar] [CrossRef]
  32. Steinbrückner, B.; Fehrenbach, J.; Philippczik, G.; Kist, M.; Bauer, T.M. Clinical significance of pure or predominant growth of Pseudomonas aeruginosa in faecal specimens of medical patients. J. Hosp. Infect. 1999, 43, 164–165. [Google Scholar] [CrossRef]
  33. Voorhies, A.A.; Lorenzi, H.A. The challenge of maintaining a healthy microbiome during long-duration space missions. Front. Astron. Space Sci. 2016, 3, 23. [Google Scholar] [CrossRef]
  34. Larcombe, S.; Hutton, M.L.; Riley, T.V.; Abud, H.E.; Lyras, D. Diverse bacterial species contribute to antibioticassociated diarrhoea and gastrointestinal damage. J. Infect. 2018, 77, 417–426. [Google Scholar] [CrossRef] [PubMed]
  35. Kim, S.W.; Peck, K.R.; Jung, S.I.; et al. Pseudomonas aeruginosa as a potential cause of antibiotic-associated diarrhea. J. Korean Med. Sci. 2001, 16, 742–744. [Google Scholar] [CrossRef]
  36. Hoff, R.T.; Patel, A.; Shapiro, A. Pseudomonas aeruginosa: An uncommon cause of antibiotic-associated diarrhea in an immunocompetent ambulatory adult. Case Rep. Gastrointest. Med. 2020, 2020, 6261748. [Google Scholar] [CrossRef]
  37. Mishra, S.; Mann, B.; Besmanos, C.; Raza, N.; Heidari, A. A unique case of Pseudomonas aeruginosa-associated diarrhea in a long-term hospitalized adult patient. Cureus 2023, 15, e39978. [Google Scholar] [CrossRef] [PubMed]
  38. Bresee, J.S.; Marcus, R.; Venezia, R.A.; et al. The etiology of severe acute gastroenteritis among adults visiting emergency departments in the United States. J. Infect. Dis. 2012, 205, 1374–1381. [Google Scholar] [CrossRef]
  39. Brad, G.F.; Sabau, I.; Simedrea, I.; Belei, O. Pseudomonas aeruginosa and antibiotic-associated diarrhea in children. Timis. Med. J. 2011, 61, 237–242. [Google Scholar]
  40. Albert, M.J.; Faruque, A.S.; Faruque, S.M.; Sack, R.B.; Mahalanabis, D. Case-control study of enteropathogens associated with childhood diarrhea in Dhaka, Bangladesh. J. Clin. Microbiol. 1999, 37, 3458–3464. [Google Scholar] [CrossRef]
  41. Lee, A. Adverse drug reactions; Pharmaceutical press, 2006. [Google Scholar] [CrossRef]
  42. Fang, L.C.; Peng, C.C.; Chi, H.; Lee, K.S.; Chiu, N.C. Pseudomonas aeruginosa sepsis with ecthyma gangrenosum and pseudomembranous pharyngolaryngitis in a 5month-old boy. J. Microbiol. Immunol. Infect. 2014, 47, 158–161. [Google Scholar] [CrossRef]
  43. De, A.; Mathurkar, H.; Baveja, S.; Manglani, M.V. Pseudomonas diarrhea in a child suffering from acute lymphatic leukemia. Indian. J. Med. Paediatr. Oncol. 2009, 30, 147–148. [Google Scholar] [CrossRef] [PubMed]
  44. Stringer, A.M.; Al-Dasooqi, N.; Bowen, J.M.; et al. Biomarkers of chemotherapy-induced diarrhoea: A clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support. Care Cancer. 2013, 21, 1843–1852. [Google Scholar] [CrossRef]
  45. Chua, L.L.; Rajasuriar, R.; Lim, Y.A.L.; Woo, Y.L.; Loke, P.; Ariffin, H. Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy. BMC Cancer 2020, 20, 151. [Google Scholar] [CrossRef]
  46. Stein, A.; Voigt, W.; Jordan, K. Chemotherapy-induced diarrhea: Pathophysiology, frequency and guidelinebased management. Ther. Adv. Med. Oncol. 2010, 2, 51–63. [Google Scholar] [CrossRef]
  47. Penteado, F.D.; Bain, V.; Durigon, G.S.; Litvinov, N.; Pereira, M.F.B.; de Sousa Marques, H.H. Shanghai fever in a healthy infant: First report in South America. Pediatr. Infect. Dis. J. 2018, 37, e278–e279. [Google Scholar] [CrossRef]
  48. Chuang, C.H.; Wang, Y.H.; Chang, H.J.; et al. Shanghai fever: A distinct Pseudomonas aeruginosa enteric disease. Gut 2014, 63, 736–743. [Google Scholar] [CrossRef]
  49. Huang, Y.C.; Lin, T.Y.; Wang, C.H. Community-acquired Pseudomonas aeruginosa sepsis in previously healthy infants and children: Analysis of forty-three episodes. Pediatr. Infect. Dis. J. 2002, 21, 1049–1052. [Google Scholar] [CrossRef] [PubMed]
  50. Chuang, C.H. Case 48. A 4-month-old infant with fever, diarrhea, followed by abdominal distention and an ulcerlike skin lesion: Community-acquired Pseudomonas aeruginosa sepsis (Shanghai fever). In Paediatric Infectious Diseases; Huang, Y.C., Lee, P.I., Chen, P.Y., Eds.; Springer: Singapore, 2023. [Google Scholar] [CrossRef]
  51. Ortí, A.; Escrig, R.; Pérez-Tamarit, D.; Otero Mdel, C.; Diosdado, N.; Muro, M.D.; Asensi, F. Pseudomonas aeruginosa infection in a previously healthy infant. Clin. Pediatr. 2002, 41, 525–528. [Google Scholar] [CrossRef]
  52. Mull, C.C.; Scarfone, R.J.; Conway, D. Ecthyma gangrenosum as a manifestation of Pseudomonas sepsis in a previously healthy child. Ann. Emerg. Med. 2000, 36, 383–387. [Google Scholar] [CrossRef] [PubMed]
  53. Yatsunenko, T.; Rey, F.E.; Manary, M.J.; et al. Human gut microbiome viewed across age and geography. Nature 2012, 486, 222–227. [Google Scholar] [CrossRef] [PubMed]
  54. Matamoros, S.; Gras-Leguen, C.; Le Vacon, F.; Potel, G.; de La Cochetiere, M.F. Development of intestinal microbiota in infants and its impact on health. Trends Microbiol. 2013, 21, 167–173. [Google Scholar] [CrossRef]
  55. Fan, Q.; Yi, M.; Liu, H.; et al. The impact of age and pathogens type on the gut microbiota in infants with diarrhea in Dalian, China. Can. J. Infect. Dis. Med. Microbiol. 2020, 2020, 8837156. [Google Scholar] [CrossRef] [PubMed]
  56. Fakhkhari, P.; Tajeddin, E.; Azimirad, M.; et al. Involvement of Pseudomonas aeruginosa in the occurrence of community and hospital acquired diarrhea, and its virulence diversity among the stool and the environmental samples. Int. J. Environ. Health Res. 2022, 32, 61–71. [Google Scholar] [CrossRef] [PubMed]
  57. Chowdhury, G.; Das, B.; Kumar, S.; et al. Genomic insights into extensively drug-resistant Pseudomonas aeruginosa isolated from a diarrhea case in Kolkata, India. Future Microbiol. 2023, 18, 173–186. [Google Scholar] [CrossRef]
  58. Adlard, P.A.; Kirov, S.M.; Sanderson, K.; Cox, G.E. Pseudomonas aeruginosa as a cause of infectious diarrhoea. Epidemiol. Infect. 1998, 121, 237–241. [Google Scholar] [CrossRef] [PubMed]
  59. Tumbarello, M.; Raffaelli, F.; Peghin, M.; et al. Characterisation risk factor profiling of Pseudomonas aeruginosa urinary tract infections: Pinpointing those likely to be caused by multidrug-resistant strains. Int. J. Antimicrob. Agents. 2020, 55, 105900. [Google Scholar] [CrossRef]
  60. Viasus, D.; Puerta-Alcalde, P.; Cardozo, C.; et al. Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infection. Clin. Microbiol. Infect. 2020, 26, 345–350. [Google Scholar] [CrossRef]
  61. Farooq, L.; Memon, Z.; Ismail, M.O.; Sadiq, S. Frequency and antibiogram of multi-drug resistant Pseudomonas aeruginosa in a tertiary care hospital of Pakistan. Pak. J. Med. Sci. 2019, 35, 1622–1626. [Google Scholar] [CrossRef]
  62. Procop, G.W.; Church, D.L.; Hall, G.S.; Janda, W.M.; Koneman, E.W.; Schreckenberger, P.C. Koneman’s color atlas and textbook of diagnostic microbiology; Jones & Bartlett Learning: Burlington, MA, USA, 2020. [Google Scholar]
Table 1. Reviewed case reports and cases’ clinical characteristics.
Table 1. Reviewed case reports and cases’ clinical characteristics.
Germs 14 00179 i001Germs 14 00179 i002Germs 14 00179 i003
CZL—cefazolin; CIP—ciprofloxacin; OFL—ofloxacin; GEN—gentamicin; MEM—meropenem; TOB—tobramycin; AMI—amikacin; AZT—aztreonam; AMK—amikacin; CTR—ceftriaxone; CTZ—ceftazidime; PIP—piperacillin; CTX—cefotaxime; CXT—cefoxitin; CTM—ceftizoxime; CRX—cefuroxime; CLT—cephalothin; IMI—imipenem; LEV—levofloxacin; COL—colistin; PTZ—piperacillin-tazobactam; VAN—vancomycin; DOX—doxycycline.

Share and Cite

MDPI and ACS Style

Khaledi, M.; Saghabashi, A.; Ghahramanpour, H. The Emerging Role of Pseudomonas aeruginosa in Diarrhea: Where We Stand. GERMS 2024, 14, 179-188. https://doi.org/10.18683/germs.2024.1429

AMA Style

Khaledi M, Saghabashi A, Ghahramanpour H. The Emerging Role of Pseudomonas aeruginosa in Diarrhea: Where We Stand. GERMS. 2024; 14(2):179-188. https://doi.org/10.18683/germs.2024.1429

Chicago/Turabian Style

Khaledi, Mansoor, Ahdiyeh Saghabashi, and Hossein Ghahramanpour. 2024. "The Emerging Role of Pseudomonas aeruginosa in Diarrhea: Where We Stand" GERMS 14, no. 2: 179-188. https://doi.org/10.18683/germs.2024.1429

APA Style

Khaledi, M., Saghabashi, A., & Ghahramanpour, H. (2024). The Emerging Role of Pseudomonas aeruginosa in Diarrhea: Where We Stand. GERMS, 14(2), 179-188. https://doi.org/10.18683/germs.2024.1429

Article Metrics

Back to TopTop